Previous 10 | Next 10 |
SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the “Rights Offering”). Under the terms of the Rights...
Gainers: Seneca Biopharma (NASDAQ: SNCA ) +126% . More news on: Seneca Biopharma, Inc., iMedia Brands, Inc., Aptinyx Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Cidara Therapeutics ( CDTX -6.1% ) is down on more than double volume, turnover of 512K shares, in response to its planned rights offering aimed at raising $30M. More news on: Cidara Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ....
Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced ...
CNS Pharmaceuticals (NASDAQ: CNSP ) initiated with Speculative Buy rating at Benchmark. More news on: CNS Pharmaceuticals, Inc., Proteostasis Therapeutics, Inc., STAAR Surgical Company, Healthcare stocks news, Stocks on the move, , Read more ...
SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at the 61 st American Society of Hematology (ASH) Annual Meeting & Ex...
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year. Ci...
Cidara Therapeutics (NASDAQ: CDTX ): Q3 GAAP EPS of -$0.08 beats by $0.18 . Revenue of $19.1M beats by $13.1M . Press Release More news on: Cidara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate a...
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on Novemb...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...